Clinical trials
Completed Acromegaly trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
127 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 2 |
| 2002 | 5 |
| 2003 | 5 |
| 2004 | 8 |
| 2005 | 4 |
| 2006 | 7 |
| 2007 | 9 |
| 2008 | 10 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 7 |
| 2013 | 7 |
| 2014 | 8 |
| 2015 | 5 |
| 2016 | 6 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 7 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 4 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 127 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ipsen | 27 |
| Novartis Pharmaceuticals | 13 |
| Pfizer | 7 |
| University of Aarhus | 7 |
| Federico II University | 5 |
| Cedars-Sinai Medical Center | 4 |
| Columbia University | 4 |
| Massachusetts General Hospital | 4 |
| Assistance Publique - Hôpitaux de Paris | 3 |
| Camurus AB | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Acromegaly | 127 |
| Pituitary Neoplasms | 11 |
| Dwarfism, Pituitary | 5 |
| Insulin Resistance | 5 |
| Neuroendocrine Tumors | 3 |
| Pituitary ACTH Hypersecretion | 3 |
| Diabetes Mellitus | 2 |
| Gigantism | 2 |
| Glucose Intolerance | 2 |
| Growth Disorders | 2 |
Trials
Showing 51 to 75 of 127. Each trial links to its page on Pharma Observatory.
27 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.